Central Kittanning & Dialyiss is categorized under Primary Care Centers in Kittanning, PA and active since 2009.
Central Kittanning & Dialyiss was established in 2009, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Primary Care Centers business, which does work in the B2C market, and is classified as a Primary Care Centers, under code number 621111 by the NAICS.
If you are seeking more information, feel free to contact Karl Goliat at the company’s single location by writing to 700 Medical Arts Building, Kittanning, Pennsylvania PA 16201 or by phoning (724) 543-3151. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Central Kittanning & Dialyiss |
| Contact Person: | Karl Goliat |
| Address: | 700 Medical Arts Building, Kittanning, Pennsylvania 16201 |
| Phone Number: | (724) 543-3151 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2009 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Primary Care Centers |
| SIC Code: | 8011 |
| NAICS Code: | 621111 |
| Share This Business: |
Central Kittanning & Dialyiss was started in 2009 to provide professional Primary Care Centers under the SIC code 8011 and NAICS code 621111. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Karl Goliat for inquiries that concern Central Kittanning & Dialyiss by calling the company number (724) 543-3151, as your correspondence is most welcome. Additionally, the physical location of the single location of Central Kittanning & Dialyiss can be found at the coordinates 40.81221,-79.47081 as well as the street address 700 Medical Arts Building in Kittanning, Pennsylvania 16201.
For its online presence, you may visit Central Kittanning & Dialyiss’s website at and engage with its social media outlets through on Twitter and on Facebook.